Author

Chelsea Elam

Observed names: C. F. Elam, Elam, Chelsea

Institution: Novartis (United States)

Observed institutions: University of Alabama at Birmingham, Novartis (United States)

OpenAlex ID: A5061745657

Metformin Supplementation and Life Span in Fischer-344 Rats

2010 · D. L. Smith, C. F. Elam, et al. · The Journals of Gerontology Series A · 153

Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study

2022 · Yang Mao-Draayer, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 10

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment

2024 · Atul Deodhar, Alan J Kivitz, et al. · Lara D. Veeken · 4

Changes in immune cell profile, clinical and safety outcomes in fingolimod-treated patients with relapsing multiple sclerosis in the FLUENT study (4249)

2020 · Yang Mao-Draayer, Jeffrey A. Cohen, et al. · Neurology

Works count: 6

Citation count: 167

H-index: 3

I10-index: 2